Novel definition of hepatorenal syndrome: Clinical consequences

Frontiers of Gastrointestinal Research

Volumn 28, Issue , 2011, Pages 122-129

  Fernandez, Javier ^a   Arroyo, Vicente ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; CYSTATIN C; SODIUM;

ACUTE KIDNEY FAILURE; ADRENAL DISEASE; ARTICLE; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CHRONIC LIVER FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE CLASSIFICATION; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; OLIGURIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; SODIUM URINE LEVEL; URINE VOLUME; VASOCONSTRICTION;

EID: 79551481736     PISSN: 03020665     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000318993     Document Type: Article

References (25)

1. Gines A, Escorsell A, Gines P, et al: Incidence, predictive factors, and prognosis of the hepatorenalsyndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
2. Gines P, Rodes J: Clinical disorders of renal function in cirrhosis with ascites; in Arrovo V, Gines P, Rodes J, Schrier RW (eds): Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Malden, Blackwell Science, 1999, pp 36-62.
3. Koppel MH, Coburn JW, Mims MM, Goldstei H, Boyle JD, Rubini ME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome: Evidence for functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-1370.
4. Gines P, Guevara M, Arroyo V, Rodes J: Hepatorenal syndrome. Lancet 2003;362:1819-1827.
5. Arroyo V, Fernandez J, Ginès P: Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
6. Ruiz-Del-Arbol L, Urman J, Fernandez J, et al: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218.
7. Guevara M, Bru C, Gines P, et al: Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998;28:39-44.
8. Caregaro L, Menon F, Angeli P, et al: Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994;154:201-205.
9. Sherman DS, Fish DN, Teitelbaum I: Assessing renal function in cirrhotic patients: Problems and pitfalls. Am J Kidney Dis 2003;41:269-278.
10. Cholangitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, Thomas M, Patch D, Burroughs AK: Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007;13:523-529.
11. Arroyo V, Gines P, Gerbes AL: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176.
12. Cabrera J, Arroyo V, Ballesta AM, et al: Aminoglycoside nephrotoxicity in cirrhosis: Value of urinary beta- 2- microglobulin to discriminate functional renal- failure from acute tubular damage. Gastroenterology 1982;82:97-105.
13. Dudley FJ, Kanel GC, Wood LJ, Reynolds TB: Hepatorenal- syndrome without avid sodium retention. Hepatology 1986;6:248-251.
14. Rodes J, Arroyo V, Bosch J: Clinical types and drugtherapy of renal impairment in cirrhosis. Postgrad Med J 1975;51:492-497.
15. Maroto A, Gines P, Arroyo V, et al: Brachial and femoral- artery blood- flow in cirrhosis: Relationship to kidney dysfunction. Hepatology 1993;17:788-793.
16. Ruiz-Del-Arbol L, Monescillo A, Arocena C, et al: Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447.
17. Uriz J, Gines P, Cardenas A, et al: Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
18. Ortega R, Gines P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with Hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002;36:941-948.
19. Duvoux C, Zanditenas D, Hezode C, et al: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-380.
20. Wong F, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
21. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318.
22. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup: Acute renal failure: Definition, outcome measures, animal models, fluid therapy and information technology needs. Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;R204-R212.
23. Ricci Z, Cruz D, Ronco C: The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008;73:538-546.
24. Cholongitas E, Calvaruso V, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK: RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol 2009;24:1639-1647.
25. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11: R31.